FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206683668> ?p ?o ?g. }

• W3206683668 endingPage "n2321" @default.
• W3206683668 startingPage "n2321" @default.
• W3206683668 abstract "To assess the effectiveness and safety of different preparations and doses of non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and paracetamol for knee and hip osteoarthritis pain and physical function to enable effective and safe use of these drugs at their lowest possible dose.Systematic review and network meta-analysis of randomised trials.Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, regulatory agency websites, and ClinicalTrials.gov from inception to 28 June 2021.Randomised trials published in English with ≥100 patients per group that evaluated NSAIDs, opioids, or paracetamol (acetaminophen) to treat osteoarthritis.The prespecified primary outcome was pain. Physical function and safety outcomes were also assessed.Two reviewers independently extracted outcomes data and evaluated the risk of bias of included trials. Bayesian random effects models were used for network meta-analysis of all analyses. Effect estimates are comparisons between active treatments and oral placebo.192 trials comprising 102 829 participants examined 90 different active preparations or doses (68 for NSAIDs, 19 for opioids, and three for paracetamol). Five oral preparations (diclofenac 150 mg/day, etoricoxib 60 and 90 mg/day, and rofecoxib 25 and 50 mg/day) had ≥99% probability of more pronounced treatment effects than the minimal clinically relevant reduction in pain. Topical diclofenac (70-81 and 140-160 mg/day) had ≥92.3% probability, and all opioids had ≤53% probability of more pronounced treatment effects than the minimal clinically relevant reduction in pain. 18.5%, 0%, and 83.3% of the oral NSAIDs, topical NSAIDs, and opioids, respectively, had an increased risk of dropouts due to adverse events. 29.8%, 0%, and 89.5% of oral NSAIDs, topical NSAIDs, and opioids, respectively, had an increased risk of any adverse event. Oxymorphone 80 mg/day had the highest risk of dropouts due to adverse events (51%) and any adverse event (88%).Etoricoxib 60 mg/day and diclofenac 150 mg/day seem to be the most effective oral NSAIDs for pain and function in patients with osteoarthritis. However, these treatments are probably not appropriate for patients with comorbidities or for long term use because of the slight increase in the risk of adverse events. Additionally, an increased risk of dropping out due to adverse events was found for diclofenac 150 mg/day. Topical diclofenac 70-81 mg/day seems to be effective and generally safer because of reduced systemic exposure and lower dose, and should be considered as first line pharmacological treatment for knee osteoarthritis. The clinical benefit of opioid treatment, regardless of preparation or dose, does not outweigh the harm it might cause in patients with osteoarthritis.PROSPERO number CRD42020213656." @default.
• W3206683668 created "2021-10-25" @default.
• W3206683668 creator A5015365351 @default.
• W3206683668 creator A5021549046 @default.
• W3206683668 creator A5022067453 @default.
• W3206683668 creator A5022756084 @default.
• W3206683668 creator A5022806614 @default.
• W3206683668 creator A5023839110 @default.
• W3206683668 creator A5038409870 @default.
• W3206683668 creator A5038554586 @default.
• W3206683668 creator A5052165923 @default.
• W3206683668 creator A5060776202 @default.
• W3206683668 creator A5061940256 @default.
• W3206683668 creator A5062526583 @default.
• W3206683668 creator A5066901401 @default.
• W3206683668 creator A5067168729 @default.
• W3206683668 creator A5069082766 @default.
• W3206683668 creator A5084659191 @default.
• W3206683668 creator A5085416123 @default.
• W3206683668 creator A5085782112 @default.
• W3206683668 date "2021-10-12" @default.
• W3206683668 modified "2023-10-16" @default.
• W3206683668 title "Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis" @default.
• W3206683668 cites W1497325838 @default.
• W3206683668 cites W1928905073 @default.
• W3206683668 cites W1973166299 @default.
• W3206683668 cites W1978738190 @default.
• W3206683668 cites W2004210035 @default.
• W3206683668 cites W2009549130 @default.
• W3206683668 cites W2010818945 @default.
• W3206683668 cites W2020387702 @default.
• W3206683668 cites W2024588402 @default.
• W3206683668 cites W2030838816 @default.
• W3206683668 cites W2033451677 @default.
• W3206683668 cites W2035833931 @default.
• W3206683668 cites W2063738853 @default.
• W3206683668 cites W2096722523 @default.
• W3206683668 cites W2099880429 @default.
• W3206683668 cites W2109621899 @default.
• W3206683668 cites W2113144077 @default.
• W3206683668 cites W2119749032 @default.
• W3206683668 cites W2135393211 @default.
• W3206683668 cites W2139898754 @default.
• W3206683668 cites W2141165366 @default.
• W3206683668 cites W2144625636 @default.
• W3206683668 cites W2148159175 @default.
• W3206683668 cites W2151217395 @default.
• W3206683668 cites W2156026866 @default.
• W3206683668 cites W2158131645 @default.
• W3206683668 cites W2161739351 @default.
• W3206683668 cites W2162969377 @default.
• W3206683668 cites W2164036238 @default.
• W3206683668 cites W2170978402 @default.
• W3206683668 cites W2253845954 @default.
• W3206683668 cites W2330496155 @default.
• W3206683668 cites W2491633544 @default.
• W3206683668 cites W2527824850 @default.
• W3206683668 cites W2612284626 @default.
• W3206683668 cites W2766988938 @default.
• W3206683668 cites W2784066347 @default.
• W3206683668 cites W2785418475 @default.
• W3206683668 cites W2790175340 @default.
• W3206683668 cites W2886531541 @default.
• W3206683668 cites W2889451581 @default.
• W3206683668 cites W2904363872 @default.
• W3206683668 cites W2908547890 @default.
• W3206683668 cites W2912858276 @default.
• W3206683668 cites W2944358359 @default.
• W3206683668 cites W2955666772 @default.
• W3206683668 cites W3000036091 @default.
• W3206683668 cites W3086296348 @default.
• W3206683668 cites W3092849554 @default.
• W3206683668 cites W3110084249 @default.
• W3206683668 cites W3174024997 @default.
• W3206683668 cites W4245966879 @default.
• W3206683668 doi "https://doi.org/10.1136/bmj.n2321" @default.
• W3206683668 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8506236" @default.
• W3206683668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34642179" @default.
• W3206683668 hasPublicationYear "2021" @default.
• W3206683668 type Work @default.
• W3206683668 sameAs 3206683668 @default.
• W3206683668 citedByCount "75" @default.
• W3206683668 countsByYear W32066836682021 @default.
• W3206683668 countsByYear W32066836682022 @default.
• W3206683668 countsByYear W32066836682023 @default.
• W3206683668 crossrefType "journal-article" @default.
• W3206683668 hasAuthorship W3206683668A5015365351 @default.
• W3206683668 hasAuthorship W3206683668A5021549046 @default.
• W3206683668 hasAuthorship W3206683668A5022067453 @default.
• W3206683668 hasAuthorship W3206683668A5022756084 @default.
• W3206683668 hasAuthorship W3206683668A5022806614 @default.
• W3206683668 hasAuthorship W3206683668A5023839110 @default.
• W3206683668 hasAuthorship W3206683668A5038409870 @default.
• W3206683668 hasAuthorship W3206683668A5038554586 @default.
• W3206683668 hasAuthorship W3206683668A5052165923 @default.
• W3206683668 hasAuthorship W3206683668A5060776202 @default.
• W3206683668 hasAuthorship W3206683668A5061940256 @default.
• W3206683668 hasAuthorship W3206683668A5062526583 @default.

• next